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Abstract
Background—Heparin induced thrombocytopenia (HIT) is a prothrombotic response to heparin 
therapy with platelet activating, anti-PF4/heparin antibodies leading to thrombocytopenia 
associated with thromboembolism.
Objective—We tested the hypothesis that anti-PF4/heparin antibodies are associated with 
thromboembolism after cardiac surgery.
Methods—This multi-center, prospective cohort study collected laboratory and clinical data up to 
30 days after surgery and longer-term clinical follow up. The primary outcome variable combined 
new arterial or venous thrombotic complications (TEC) with all-cause death until 90 days after 
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surgery. Laboratory analyses included platelet counts and anti-PF4/heparin antibody tires (GTI 
ELISA, Waukesha, WI), with a confirmatory excess heparin step and serotonin release assay. Chi-
squared testing was used to test the relationship between our outcome and HIT antibody 
seropositivity.
Results—Initially, 1021 patients enrolled between August 2006 and May 2009, follow-up was 
completed in December 2014. Seropositivity defined by OD > 0.4 was common, almost 20% 
preoperatively, over 30% by discharge and over 60% by Day 30. Death (1.7% within 30 days) or 
TEC (69 total) was more likely if seronegative (OD < 0.4), but defining positive by OD > 1.0 or 
including an excess heparin confirmatory step resulted in equal incidence of death or TEC whether 
seronegative or seropositive. Incorporating the serotonin release assay for platelet activating 
antibodies did not alter these findings.
Conclusions—Seropositivity for anti-PF4/heparin antibodies does not increase the risk of death 
or thromboembolism after cardiac surgery. Screening is not indicated and seropositivity should 
only be interpreted in the context of clinical evidence for HIT.
Keywords
Thrombocytopenia; heparin induced thrombocytopenia; thoracic surgery; thrombosis; 
thromboembolism
INTRODUCTION
Heparin-induced thrombocytopenia (HIT) is one of the most clinically important drug-
induced complications in hospitalized patients. This paradoxical, prothrombotic response to 
anticoagulant therapy is an immunologic condition in which antibodies to a complex of 
endogenous platelet factor 4 (PF4) and exogenous heparin activate platelets, leading to 
aggregation, thrombocytopenia, and, potentially, thromboembolic complications [1,2]. 
Treatment requires the cessation of heparin and initiation of an alternative anticoagulant, as 
symptomatic arterial or venous thrombosis associated with a high mortality may develop in a 
third to half of the patients with HIT who present with isolated thrombocytopenia [3–5].
Seropositivity to PF4/heparin complexes in cardiac surgery patients is common [6–9]. The 
actual incidence of HIT in patients undergoing cardiac surgery, however, is reportedly much 
lower, typically 0.5% to 1.8% [10–12]. Platelet count profiles may be helpful in determining 
the likelihood of HIT in a patient with thrombocytopenia following cardiopulmonary bypass 
surgery [13], but this has not been consistently observed [11]. This complicates the diagnosis 
of HIT and potentially exposes patients to hemorrhagic risks if they are treated with less 
familiar, non-heparin anticoagulants to treat false positive cases of HIT. However, anti-PF4/
heparin antibodies in the absence of thrombocytopenia may not be entirely benign. For 
example, elevated antibody levels are associated with myocardial infarction at 30 days in 
non-thrombocytopenic patients presenting with acute coronary syndromes [14], 
arteriovenous fistula thrombosis in non-diabetic hemodialysis patients [15] and increased 
likelihood death or prolonged hospitalization after cardiac surgery, [16] although direct 
causality remains unproven. Still, heparin remains the anticoagulant of choice for over 
250,000 cardiac surgeries performed in the US each year [17]. Up to half of these patients 
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will develop anti-PF4/heparin antibodies, and up to 4,500 are projected to develop HIT each 
year. While previous studies suggest an independent thrombotic risk from seropositivity 
[18], it remains essential to critically evaluate the relationship between anti-PF4/heparin 
antibodies and thromboembolism in a population that reflects current clinical and laboratory 
practice, and is adequately powered to evaluate uncommon thromboembolic events.
The overall aim of our study is to prospectively determine the time-course of anti-PF4/
heparin antibody production and their relationship to thromboembolic events, from the day 
of surgery to 3 months after surgery, and long-term survival. These data will allow us to 
definitively test the hypothesis that anti-PF4/heparin antibodies are associated with 
thromboembolism and reduced survival after cardiac surgery.
METHODS
Study Population
All patients undergoing cardiac surgery requiring cardiopulmonary bypass with heparin 
anticoagulation were eligible for study. Exclusion criteria included planned post-operative 
anticoagulant therapy during the hospital stay with warfarin, therapeutic dose low-molecular 
weight heparin, or therapeutic unfractionated heparin. The study was approved at the 
Institutional Review Boards at each participating site, and written informed consent was 
obtained from all participants.
Study Design and Measurements
The multicenter, prospective cohort study was conducted through the Rare Thrombotic 
Diseases Consortium (ClinicalTrials.gov #NCT00237328), and patients were enrolled at five 
participating centers (Duke University Medical Center, Durham Veterans’ Administration 
Medical Center, Mayo Clinic, the University of Wisconsin, and the University of North 
Carolina). Lysine analog anti-fibrinolytic agents were routinely used at all institutions.
Information collected at baseline included patient characteristics (including self-reported 
race and ethnicity), risk factors for thrombosis (including race), preoperative co-morbidities 
and operative details. Subsequently, information including all thrombotic events, 
transfusions, details of hospital readmissions, platelet counts, and utilization of 
antithrombotic medications in the postoperative setting was collected daily during 
hospitalization, then at the postoperative Day 30 and Day 90 follow-up time points. These 
collections were standardized by using a structured interview format with detailed 
questionnaires.
Collected data were transferred to an online data entry form by the staff member conducting 
the interview or test. Unique, de-identified study subject information was transmitted via 
encrypted virtual private network to a centralized, password protected database housed at the 
Data and Technology Coordinating Center (University of South Florida, Tampa, Florida) 
designed by the Rare Diseases Clinical Research Network. Online forms incorporated 
checks to minimize transcription and omission errors, including internal validity checks for 
reasonableness and consistency. Regular assessments of data quality were performed and 
automatically generated reminders helped keep follow-up evaluations within timeframe. All 
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outcome events were independently reviewed and coded by two independent reviewers to 
define and assign a date to an event. Strict case definitions were used to minimize reviewer 
discordance, which was arbitrated by the PI without knowledge of laboratory or other patient 
data.
All deaths and alternative anitcoagulant use in this period were independently adjudicated 
for their potential relationship to complications associated with anti-PF4/heparin antibodies.
Laboratory samples were collected at baseline, Day 5 (pre-discharge), and Day 30, 
processed, and stored at −80°C until testing was performed centrally at Duke University. The 
anti-PF4/heparin ELISA was performed using the Enhanced GTI kit, which detects IgG, 
IgM, and IgA anti-PF4/heparin antibodies (GTI, Waukesha, WI); specific IgG isotype assays 
were not commercially available at the time the study was open. A ‘high-heparin’ 
confirmatory test was performed on all samples with an absorbance optical density (OD) > 
0.40, as previously described, and a positive result was defined as >50% inhibition of 
binding [19]. Data analysis was also performed using an OD cutoff of >1.0 units, which has 
been reported to increase the specificity of this assay [20]. Serotonin release assays were 
performed on samples from patients who were seropositive by both antibody titer and 
heparin confirmatory step, and reported as previously described [21].
Outcome Measures
The primary, combined end-point was all-cause death and/or new venous or arterial 
thromboembolic complications (TEC), including miscellaneous events compatible with HIT, 
occurring from the time of surgery up until 90 days after surgery. Informed consent included 
permission to interview next of kin/health care power of attorney and review the medical 
record to determine cause of death. Long-term follow-up was obtained from the Duke Death 
Registry that uses medical records and the National Social Security database as sources.
Statistical Analysis
A sample size of 800 patients was estimated to detect a 3% difference in thromboembolic 
events, assuming a 2 to 10-fold increased risk attributable to seropositivity and a 25–50% 
incidence of seropositivity. After the first 400 subjects had completed the protocol, an 
analysis blinded to antibody status determined outcome rate, re-estimated sample size and 
confirmed our original estimate of 800 patients requiring complete follow-up data. 
Assuming an attrition rate of 20%, we targeted enrollment of over 1000 patients.
Demographic data and other characteristics are described as numbers and percentages and 
their distribution as mean +/− standard deviation or median with interquartile range, as 
appropriate. The evolution of antibody status with time complicated a “time to event” 
analysis; therefore, the Chi square statistic was used to test the relationship between death or 
TEC, and antibody status, as defined by ELISA, OD, heparin confirmatory testing and the 
serotonin release assay. The laboratory value (positive/negative) preceding an event (if yes) 
or that preceding the last follow-up (if no) was related to outcome (yes/no). A p-value of 
0.05 was considered statistically significant and no adjustment was made for multiple 
comparisons. Kaplan-Meier curves were drawn to demonstrate the effect of seropositivity on 
survival; Cox proportional hazards modeling, adjusted for Euroscore mortality risk, and 
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calculated the hazard ratio associated with seropositivity for those with available laboratory 
data at day 30 and evaluable data to calculate Euroscore.
Role of the Funding Source—NIH U54 HL77878 (PI Dr. T Ortel) funds the Rare 
Thrombotic Diseases Clinical Research Network and supported this study. The study design 
was approved by NIH reviewers prior to funding; the conduct and reporting of this study was 
solely performed by the investigators.
RESULTS
A total of 1030 eligible patients were enrolled between August 2006 and May 2009. Eight 
patients withdrew from the study, and data from one patient were missing. Complete 
demographic information was available for 990 patients (Table 1). Missing outcome (n=18) 
or laboratory (n=26) data resulted in a primary analysis dataset of 946 patients, which 
excluded 4 patients suffering death or TEC (Figure 1). The patient demographics differ little 
based on HIT antibody status, although seronegative patients had a higher incidence of 
previous arterial thrombosis, hormone replacement therapy or cardiac catheterization (Table 
1). The average age of all patients with complete demographic data was 62 ± 12 years, and 
74.6% of participants were male. Overall, 75% of patients underwent coronary artery bypass 
grafting (CABG). The remainder underwent more complex cardiac surgery; there were 6 
reoperations, with 4 performed for internal bleeding. In the post-operative period, 
prophylactic heparin was administered to 39 patients (4.8%) and therapeutic heparin to 41 
patients (5.1%).
Outcome measures
Up to 3 months after surgery, there were 17 deaths (1.7%) and 69 TECs affecting a total of 
78 patients, as detailed in Table 2. One death was adjudicated as possibly HIT related and 
the remainder was considered unrelated. Using the standard, low titer cut-off (OD > 0.4), 8 
of 17 patients who died were seropositive and the remaining 9 were seronegative. The Day 
30 anti-heparin/PF4 antibody result in the patient who died with possible HIT was 0.46 and 
the two patients with confirmed thromboembolism who died were both seronegative prior to 
their deaths.
Of the 69 thromboembolic events, 3 (4.3%) occurred before postoperative day 5, classifying 
them as early complications. Four patients suffered pre- and post-discharge TECs and two 
suffered multiple TECs, one of whom died. While most patients (37/69 or 53.6%) with a 
TEC were seropositive, the high prevalence of a positive antibody titer led to no significant 
association between seropositivity and TEC (see Table S1).
Seven patients were treated with a parenteral, non-heparin anticoagulant in the postoperative 
setting (4 with bivalirudin, 2 with argatroban, and 1 with fondaparinux). Subsequent 
adjudication by study personnel of non-heparin anticoagulant use in these 7 patients (see 
Table S2) determined that 4 cases were unrelated, 1 was unlikely, 1 was probably, and 1 was 
definitely related to HIT. Day 30 ELISA optical densities for the latter 2 patients were 2.19 
and 0.62, respectively.
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Laboratory Testing
Seropositivity, when defined as an OD >0.4, was seen in the majority of patients by Day 30 
(613 of 946, 65%). The more stringent definitions of OD > 1.0, OD > 0.4 with > 50% excess 
heparin confirmatory step, and OD > 1.0 with > 50% excess heparin confirmatory step 
generated a positive test result in 216 of 946 (23%), 466 of 927 (50%; 2% missing) and 184 
of 942 (20%; 0.4% missing), respectively. The evolution of antibody status is illustrated in 
Figure 2, demonstrating how common a positive result is using the definition of OD > 0.4. 
The relationship between the 4 definitions of a positive anti-PF4/heparin antibody test and 
clinical events are detailed in Table S1
Based on TEC event timing, 26 patients sustained their TEC after Day 30, using Day 30 
results as their index laboratory assay, 45 sustained their TEC between days 5 and 30, using 
Day 5 laboratory data, and 3 sustained their TEC before Day 5, using their preoperative 
laboratory data to test for an association between anti-heparin/PF4 antibodies and death or 
TEC. Of note, 127 patients who were missing the Day 30 results were included in the 
analysis dataset by evaluating Day 5 as index laboratory tests and the subsequent Day 5-Day 
30 follow-up period for evaluation of events.
Baseline platelet counts were 287 (+/−102) x109/l with a postoperative nadir of 130 (+/−54) 
x109/l, a 54% decrease. Similar platelet count patterns were seen for seronegative and 
seropositive patients (supplemental data Fig S1). Patients experiencing a TEC displayed a 
similar platelet count pattern to the remainder (data not shown).
Chi-squared testing using 2×2 tables constructed from antibody status positive/negative and 
clinical event yes/no identified that 11% of those with an OD < 0.4 suffered death or TEC, 
while 6% of those with an OD > 0.4 suffered death or TEC (p = 0.013). In contrast, there 
were no significant relationships identified between events (death and/or TEC) and anti-PF4/
heparin antibody test status when this was defined as high titer (OD > 1.0) or a heparin 
confirmatory step was added to a low or high positive titer (see Table S1). The serotonin 
release assay was performed on a sub-set of patients positive by both titer (OD > 0.4) and 
heparin confirmatory step and did not differentiate between those who subsequently suffered 
death and/or a TEC (data not shown).
Long Term Outcomes
This pattern persisted during follow-up. Post-hoc, long term follow-up data were available 
for 669 patients with D30 antibody titers, with matching Euroscores in 540 patients. The 
average duration of long-term follow up was 3.3 years for non-survivors and 6.7 years for 
survivors. Figure 3 illustrates reduced survival in seronegative patients with a hazard ratio 
[95% CI] for death of 1.77 [1.18–2.64] compared to those seropositive (OD > 0.4), after 
adjusting for Euroscore mortality risk (p=0.0053). This significant association between 
seronegativity (seropositive if OD > 0.4) and reduced survival was only present for this low 
titer definition (see Table S3).
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DISCUSSION
We prospectively evaluated early and delayed thromboembolic events and long-term survival 
after cardiac surgery. Seropositivity was defined as either low titer (OD>0.4), high titer (OD 
> 1.0), heparin dependent (reduction in antibody/antigen binding following addition of 
excess heparin) or capable of activating platelets (SRA reactivity), yet the only association 
we found was with low titre seropositive status (OD > 0.4) and a lower incidence of death or 
thromboembolic events. This unexpected finding may be explained by the confounding 
effect of a greater incidence of prior arterial thrombosis, actively treated cancer and 
hormonal therapy usage in the seronegative group, and was not investigated further. 
Therefore, in the absence of a clinical suspicion for HIT, we reject the hypothesis that early 
or late thromboembolism is associated with the development of anti-PF4/heparin antibodies 
after cardiac surgery.
This is currently the largest prospective series designed to relate pre-defined 
thromboembolic events to the evolution of the perioperative anti-PF4/heparin antibody 
response. In keeping with our findings, smaller, prospective series (n > 200 but < 500) have 
described a similar incidence of preoperative and early postoperative anti-PF4/heparin 
antibodies [6,7,9,22] that are also unrelated to all-cause thromboembolism. Later in the 
postoperative period, the 70% seropositivity incidence we describe after 4 weeks is 
consistent with the 52% incidence of anti-PF4/heparin antibodies previously measured 6 
weeks after surgery reported by Gluckman, et al [9]. They found no relationship between 
antibodies and evidence of early saphenous vein graft thrombosis that they observed in a 
third of the 368 patients.
Notably, a prospective study by Mattioli et al reported that anti-PF4/heparin antibodies in the 
early postoperative period conferred considerably increased risk of thrombotic events for up 
to one year [18]. However, the rates of thromboembolism and mortality in that series greatly 
exceeded those we report, complicating comparison of the two studies. Retrospective series 
have also reported an increase in thrombotic complications associated with HIT limited to 
pulmonary embolism [23] or intracardiac thrombosis diagnosed by echocardiography [10], 
but anti-PF4/heparin antibodies were only measured if clinically indicated in these studies. 
In contrast, we systematically tested for anti-PF4/heparin antibodies in all patients regardless 
of clinical suspicion for HIT.
Antibody status
The definition of a “positive” anti-PF4/heparin antibody test remains controversial. 
Antibodies represent a polyclonal response to the complex antigen formed by the binding of 
the cationic platelet factor 4 protein, released from the alpha granules of activated platelets, 
and the glycosoaminoglycan moieties of heparin, producing IgA, IgG and IgM isotypes. 
Most commercially available anti-PF4/heparin antibody ELISA kits detect all 3 isotypes, 
while antibodies capable of activating platelets are typically of the IgG isotype [24–27]. 
Lack of isotype specificity may reduce the overall specificity of a positive test [27,28], 
although Selleng, et al [22] noted no association between pre- or post-operative IgG 
antibodies and thromboembolism but rather an association between IgM antibodies and non-
thrombotic complications after cardiac surgery. Larger studies to confirm this relationship 
Welsby et al. Page 7
J Thromb Haemost. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
between IgG antibodies and outcomes would still be worthwhile. This possible pro-
inflammatory link seems plausible, as trauma, and the accompanying inflammatory 
response, promotes anti-PF4/heparin antibody production in the postoperative period [29]. 
The intense inflammatory stimulus of cardiopulmonary bypass may act as an adjuvant, 
promoting the formation of non-pathologic antibodies that neither activate platelets nor lead 
to HIT but, rather, are a non-specific epiphenomenon of a pro-inflammatory state.
The serotonin release assay identifies only platelet activating antibodies and is regarded as a 
gold standard test for pathologically relevant anti-PF4/heparin antibodies [30,31]. A positive 
serotonin release assay is associated with a high likelihood of true HIT, including thrombotic 
complications, when clinical suspicion of HIT exists, but is typically unavailable to 
clinicians in a timely manner [32,33]. However, in asymptomatic patients recovering from 
cardiac surgery, we found no association between a positive serotonin release assay and all-
cause death or thromboembolism.
Thrombocytopenia Incidence rates of HIT up to 5%, have been described after retrospective 
study [34], but we observed a lower incidence of HIT, similar to recent, prospective studies 
[11,23,35]. We did not combine patterns of postoperative thrombocytopenia [36,37] with 
anti-PF4/heparin antibody results to diagnose HIT retrospectively; the HIT episodes we 
report were diagnosed by the clinical team, as study related ELISA results were not available 
at the time of hospitalization. However, we found that platelet counts did not differ between 
those who did or did not develop either all-cause thromboembolism or anti-PF4/heparin 
antibodies. (Fig S1).
Limitations
One limitation of our study design and analysis was the relatively low incidence of 
thromboembolism requiring caution when extrapolating our findings to higher risk cases or 
those requiring obligatory, postoperative anticoagulation. Determination of thromboembolic 
events relied on clinical diagnoses by the attending physicians, not by sensitive imaging such 
as duplex ultrasound or transesophageal echocardiography [10]. While only used in this 
study if clinically indicated, routine imaging may have detected more thrombotic 
complications, some of which may have only become clinically evident after our 90 day 
follow-up, or remained occult. Direct thrombin inhibitor use was infrequent (0.8%) and 
unlikely to substantially reduce event rates; only one of these patients experienced HIT 
related thromboembolism. However, the possibility of Type II error from a low event rate 
does not negate our findings, as gross underpowering of the study is unlikely. Evaluation of 
over 800 patients approximates the annual caseload of a major cardiac surgery program, yet 
not even a trend towards an association between anti-PF4/heparin antibodies and 
thromboembolism was seen.
The pathogenesis of HIT has been extensively studied and well described [5,38]; our data do 
not question that anti-PF4/heparin antibodies are the agent of HIT and can lead to 
thrombosis. However, it seems evident that the anti-PF4/heparin antibodies commonly 
observed after cardiac surgery are not associated with early or delayed thromboembolism. 
They do not, therefore, stand alone as a risk factor for thromboembolism, in contrast to 
associations described after acute coronary syndrome [14] or during dialysis [15]. It is 
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plausible that the almost ubiquitous use of aspirin [39] after cardiac surgery interrupts the 
pathogenesis of HIT by altering platelet factor 4 release, anti-PF4/heparin antibody binding 
or platelet activation [40,41]. While antiplatelet agents do not universally prevent HIT [42], 
their use may explain why anti-PF4/heparin antibodies do not predict graft thrombosis 
during dialysis [43] or after peripheral vascular surgery [44] and are also not associated with 
thromboembolism after cardiac surgery.
The American College of Chest Physicians Consensus Conference Guidelines (9th edition) 
recommends that routine testing for anti-PF4/heparin antibodies before cardiac surgery 
should be avoided and that a diagnosis of HIT should be considered if the platelet count falls 
by more than 50% between days 5 and 14 following initiation of heparin therapy [30]. Our 
data confirm that anti-PF4/heparin antibody seropositivity is common in the postoperative 
period. Because postoperative thrombocytopenia is also common after cardiac surgery, 
careful clinical evaluation of platelet profile and the timing of HIT antibody testing is 
needed to avoid a false positive diagnosis of HIT [11,23,33,45].
In conclusion, a positive polyclonal anti-PF4/heparin antibody ELISA following cardiac 
surgery is common but does not predict future thromboembolism. Treating an incidental 
positive test is, therefore, unnecessary in the absence of a clinical diagnosis of HIT and 
screening all thrombocytopenic cardiac surgery patients for anti-PF4/heparin antibodies is 
not warranted.
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Essentials
• We evaluated antibody status, thromboembolism and survival after cardiac 
surgery.
• Positive antibody tests are common – over 50% are seropositive at 30 days.
• Seropositivity did not increase thromboembolism or impair survival after 
cardiac surgery.
• Results show heparin induced thrombocytopenia antibody screening after 
surgery is not warranted.
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Figure 1. 
The primary analysis dataset included only patients with evaluable demographic, laboratory 
and outcome data (n=946). The index value is the laboratory test preceding an event, or the 
D30 blood draw, if no event occurred. Note that if a patient had one or more TEC, this is 
counted as 1 event in this figure.
Abbreviations: TEC, Thromboembolic complication; D30, The study timepoint 
approximately thirty days after surgery; D5, The study timepoint approximately five days 
after surgery; PRE-OP, The preoperative study timepoint.
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Figure 2. 
This figure depicts the percentages of patients testing seropositive by low titre (OD > 0.4) 
and high titre (OD > 1.0) anti-PF4/heparin antibody definitions at preoperative, 
postoperative day 5 and postoperative day 30 timepoints. Adding a confirmatory step of 
heparin dependent binding (>50% reduction in optical density after the addition of excess 
heparin) reduces the number of seropositive patients by approximately one third in the low 
titre and one quarter in the high titre columns.
Welsby et al. Page 15
J Thromb Haemost. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. 
This survival curve is based on the Cox proportional hazards model, adjusted for the 
Euroscore mortality risk, and illustrates the improved survival in patients seropositive (OD > 
0.4) after surgery.
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Table 1
Patient characteristics by anti-PF4/heparin antibody status
Characteristics of the study population, including prior anticoagulant exposure, mostly expressed as the 
number and percentage of the total with the listed characteristic. Positive antibody status is defined as an OD > 
0.4 either pre-event or at the follow-up visit 30 days after surgery.
Demographics Negative
(n=363)
Positive
(n=627)
P
value
Age (mean+/− SD) 62.5 (11.7) 60.7 (11.8) 0.06
Gender (% female) 25.1 28.6 0.24
Race
   African American 11.0 13.6 0.25
   Native American 3.9 4.9 0.43
   White 85.4 81.5 0.11
   Hispanic ethnicity 1.4 1.4 0.94
Body mass index (kg/m2) 28.8 (6.2) 29.4 (5.8) 0.15
Co-morbidities/risk factors
Diabetes 35.2 36.1 0.79
Hypertension 73.7 71.9 0.55
History of cancer 19.3 15.8 0.16
   In remission 16.5 14.8 0.48
   Undergoing therapy 2.8 1.0 0.03
Smoker
   Current 11.6 11.2 0.85
   Former 55.1 53.6 0.64
Hypercholesterolemia 72 69 0.33
End stage renal disease (kidney failure) 11.1 9.9 0.57
Prior hemodialysis graft thrombosis 33.3 0 0.94
Hormone replacement or oral contraceptive* 9.9 3.9 0.05
Miscarriage 25.3 22.7 0.64
Previous MI 42.0 36.1 0.07
Previous stroke 9.9 9.1 0.67
Previous HIT diagnosis 0 0.5 0.19
Enoxaparin or dalteparin 8.0 7.7 0.85
Intravenous heparin 41.3 38.3 0.34
Any prior venous thrombosis 5.0 3.5 0.26
Any prior arterial thrombosis 47.1 39.2 0.02
Current warfarin use 2.5 2.2 0.80
Preoperative
Prior cardiac surgery 6.1 6.1 0.99
Prior cardiac catheterization 96.4 92.4 0.01
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Demographics Negative
(n=363)
Positive
(n=627)
P
value
Prophylactic anticoagulant use 21.6 19.0 0.32
Abbreviations used include: SD, Standard deviation; MI, Myocardial infarction; HIT, Heparin induced thrombocytopenia; LMWH, Low molecular 
weight heparin; UFH, Unfractionated heparin; OD, Optical density.
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Table 2
Deaths and thromboembolic events
During the study period, a total of 17 deaths (Section A) and 69 thromboembolic events (Section B) were 
sustained by 78 patients. Events are segregated into the segments of the study during which they occurred 
(from enrollment to Day 5; from Day 5 to Day 30; and from Day 30 to Day 90).
A. Deaths
Timing Cause of Death
Before Day 30 (n=6) Cardiac arrest (n=1)
Cardiac failure (n=1)
Complications of diabetes (n=1)
Renal failure (n=1)
Trauma-induced subarachnoid hemorrhage (n=1)
Unknown (n=1)
Days 30–90 (n=11) Cardiac arrest (n=1)
Cardiac failure (n=1)
Myocardial infarction (n=1)
Malignancy, respiratory failure (n=1)
Sepsis (n=2)
Ruptured thoracic aortic aneurysm (n=1)
Unknown (n=4)
B. Thromboembolic Events
Before Day 5 (n=3) Peripheral arterial thrombosis and VTE (n=1)
Thrombotic stroke/TIA (n=1)
VTE (n=1)
Days 5–30 (n=46) HIT/HITT (n=5)
VTE (n=21)
Acute coronary syndrome/MI/graft thrombosis (n=5)
Thrombotic stroke/TIA (n=10)
Left atrial appendage thrombosis (n=1)
Peripheral arterial thromboembolism (n=2)
Unspecified thrombosis/IVC filter placement (n=2)
Days 30–90 (n=20) HITT (n=1)
VTE (n=8)
Acute coronary syndrome/MI/graft thrombosis (n=7)
Thrombotic stroke/TIA (n=3)
Peripheral arterial thromboembolism (n=1)
Abbreviations used include: VTE, venous thromboembolism; TIA, transient ischemic attack; HIT, heparin induced thrombocytopenia; HITT, 
heparin induced thrombocytopenia and thrombosis; IVC, inferior vena cava.
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